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1. Introduction
By virtue of the dynamic nature of the scientific process, the description of the pathogenesis
of a disease is always a work in progress. Each day new research shapes and refines our
understanding of disease processes; an attempt to describe the current scientific understanding
provides merely a snapshot of a body of knowledge that is constantly changing. However,
characterizing a disease using homeostatic and physiological terms allows the creation of a
framework to convey the most up-to-date theories while maintaining the potential for their
evolution.
The complex nature of psoriasis can similarly be unveiled through understanding the historical
context of our current understanding, examining prevailing hypotheses, and extrapolating
horizons for new research. To develop a framework for understanding the pathogenesis of
psoriasis and its evolution, the first perception to be changed is the prevalent view of the
immune system. The general notion of the immune system as a defense arrangement that
protects us against the microorganisms must be changed. This view results from a reduction
of the process itself and, as mentioned by Dr. Nelson Vaz, are features derived from the birth
of the immunology [1]. Immunology, as a scientific field, is new in the history of medicine.
Immunology developed in a century marked by the First and Second World War and Cold
War tension. Hence, many models to exemplify the immunological concepts were simplified
and described in relation to war affairs to facilitate the understanding of this science. In this
model, if a microorganism attacks a human being, the individual advocates the use of the
immune system to counteract. Another simple aspect is the teleology that prevails in the
immune science. For example, the T lymphocyte exists to kill cells infected with intracellular
parasites. This model full of logic and consequences does not apply in many other areas of
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medical and non-medical sciences. As such, it is necessary to move to a new approach to
describing the relationship between the immune system and environment. In this new
paradigm, the immune system does not react, but rather interacts with the environment, and
this contact is made through the skin and mucous membranes. This interaction, causal or not,
can have different results. In most cases, there is a balance, imperceptible to other sensory
systems, which is characterized by the integrity of what we call health. Thus, homeostasis
disorders or imbalances lead to disease. This seems obvious when written, but this search for
stability has continuity for the duration of the life of a given organism. If we consider the
immune system a sensorial system, it interacts with the modifications of the environment,
detects this information of change, and responds with adjustments to maintain homeostasis.
You might reduce this view by comparing it to an engine that runs under different types of
fuel mixture. It detects the different fuel composition and changes the compression ratio of the
cylinder for better efficiency to keep the car moving.
For better observation of this psoriasis pathogenesis, we will make a technical simulation of
the immune system in a specific situation. This simulation will cover various aspects of
immune response, spanning from the beginning of the inflammatory response, to specific
immune response through the development of psoriasis. Here, under a historical perspective
and comparing with a chess game, the main objective is to provide insights on the central role
of some of these cytokines and immunological pathways in psoriasis pathophysiology.
Through this, the aim is to explain some facts of modern immunodermatology that might be
useful for clinicians to understand the basis of the immunology of psoriasis. Moreover, an
important goal is to dispel some misinformation that might have a negative impact on the use
of new immunomodulators and medications available for use by physicians. Treatment basis
and therapeutic response experience strongly supports the use of immunomodulators as
important modalities in the treatment of psoriatic arthritis and plaque psoriasis. Studies with
these therapeutic agents, which act in different steps of the psoriatic inflammatory cascade,
have also shown significant efficacy. [2].
Directly targeting this inflammatory cascade, blocking specific cytokines is a modern treatment
option for psoriasis and other autoimmune diseases [3]. The rationale for this therapy arises
from pathophysiology; in different autoimmune diseases there is an increase in production of
proinflammatory cytokines by the immune system. Inflammatory cytokines, like many other
cytokines, have an important role in both maintaining health and participating in disease
manifestation [4]. This chapter discusses the pivotal role of some of these cytokines in psoriasis
pathophysiology, how our understanding of its mechanism evolved, and how blocking the
effect of a specific cytokine might substantially improve the disease condition.
2. Pre–biologic immunological history of psoriasis
Psoriasis is a common skin disease with extra-cutaneous manifestations. It is characterized by
chronic inflammation of the skin with changes in the maturation of keratinocytes, which is
manifested by the hyperproliferation of the epidermis. Moreover, inflammatory reaction can
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be found in other systems of the same patient. However, this disease is mediated by T
lymphocytes, orchestrated by orchestration multigenic and environmental factors. The altered
immune system is essential for the inflammation present in both the skin and other organs. A
concept of a multi-systemic disorder involving different organs of the patient and reflects a
better understanding of the complex pathophysiology of this disease [2].
The concept of biological therapy for psoriasis has been derived from its etiopathogenesis. As
in a chess game, these new forms of treatment have evolved from an integration of the
knowledge of interactions between the immune system cells (pieces) and its cytokines
(movements) that initiates the pathologic processes and ultimately leads to the development
of the clinical features of psoriasis.
In ancient records, the initial causes of psoriasis were attributed to multiple sources ranging
from the divine power to racial associations [5]. An unknown infectious organism was
indicated as a source of psoriasis in 1927 [6]. Later, its etiology was described as primarily and
essentially an epidermal problem, independent of immunologic phenomena [7]. The main
objective of cytotoxic drugs developed in the 20th century, such as methotrexate, was to reduce
keratinocyte proliferation. Immunological studies on psoriatic patients identified changes in
humoral immune reactions as part of the overall problem but not the cause [8, 9]. Efficacy of
the cytotoxic drugs in the late 1960s paved the road for ideas about the role of the immune
system in psoriasis [10, 11]. Further investigations in the 1970s revealed the role of immuno‐
logic factors in psoriasis. However, the dominant thought was that psoriasis was a disease of
faulty epidermopoiesis due to impaired autocontrol mechanisms [12]. Hunter et al. wrote
“More work on cell turnover and its regulation will give the clue to psoriasis” [13].
Other studies in the 1970s revealed the role of immunologic factors in psoriasis. Histopatho‐
logic examination of psoriatic lesions showed a striking resemblance to cellular inflammatory
reactions observed in allergic contact dermatitis [14]. A selective immunosuppressant effect
was the initial hypothesis used to describe the pathological cellular immune response [15].
Soon thereafter, the discovery of a soluble factor that played an important role in keratinocyte
proliferation helped to form the cytokine-based theory for the induction/maintenance of the
inflammatory and proliferative cascades of psoriatic lesions [16]. Subsequently, an integrated
theory explaining the etiopathogenesis of psoriasis came into play: in a genetically susceptible
patient, immunological factors trigger rapid turnover in the epidermis resulting in the
development of psoriasis [17].
The fundamental confirmation that any defect of the skin is not sufficient by itself to maintain
a psoriatic lesion occurred in the subsequent decade. Some studies confirmed that T cells and
soluble factors could stimulate keratinocyte proliferation. Immunophenotyping of psoriatic
lesions showed mixed T lymphocyte (TL) cell populations (CD4 and CD8) and Langerhans
cells (LCs) distinct from normal skin [18]. This cellular infiltrate changed with topical or
systemic treatment [19, 20]. In another study, failure of plasma exchange and leukapheresis
ruled out the major participation of humoral immune system in the pathogenesis of psoriasis
[21]. Thus, the cellular arm of the immune system was implicated in psoriasis for the first time
during the 1980s [22].
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During the 1990s, research on immunopathogenesis of psoriasis thus focused on the cellular
and the cytokine components of the immune system. Researchers observed that an influx of
activated T lymphocytes, mainly CD4+, HLA-DR+, Interleukin (IL)-2 receptor - CD25+ T cells,
was one of the earliest events of psoriasis [23]. Based on Mosmman and Coffman’s publication
[24], these T lymphocytes were classified as T helper (Th) type 1 cytokine producers (Th1) [25].
They produce Interferon (IFN)-γ, IL-2, and Tumor Necrosis Factor (TNF)-α cytokines and
implied that a cellular type 1 reaction was responsible for psoriasis (Figure 1). The observation
of the historical evolution of the extra-cutaneous manifestations of psoriasis and their patho‐
genesis confirms the idea of a multi-organ disease with complex immunological pathways [2].
Figure 1. Time line of development of psoriasis pathophysiology: From unknown to epidermal problem through Im‐
munological disease.
3. Psoriasis: Many pieces and movements on a complex chessboard
Psoriasis plaque is induced and maintained by multiple interactions between cells of the skin
and immune system. It seems that the pathogenesis of psoriasis could involve a stage of cellular
infiltration resulting in epidermal (keratinocyte) proliferation. Each inflammatory pathway
(IL-12/Th1, IL-23/Th17, and IL-22/Th22) has its impact on psoriasis development [26]. The
different pathways are based on the fact that T helper cells can be skewed towards mutually
exclusive subtypes on the basis of the cytokine environment [27, 28]. The process of T lym‐
phocyte reactivation results from interaction of T cells with the resident antigen presenting
cells (APCs) found in plaque psoriasis, which in turn determines the cytokine environment
and Th1/Th17/Th22 pathway.
The primary etiopathogenesis of an autoimmune disease, or the activation of Th1/Th17/Th22
pathways, is the dysregulation of immune system activation since the development of
autoreactive lymphocytes occurs in the same basic manner as lymphocyte activation. The
understanding of this process or processes is very important to maintain the balance of the
normal performance of the immune system. Briefly, it is comparable to the process to find the
moment where one player lost the chess game based on the retroactive analysis of his moves.
Cytokines are the possible moves of different pieces of the game. Many pieces can produce the
same movement but with different results. The moves are the key players in generating or
establishing a specific immune system reaction. Therefore, blocking cytokines that maintain
autoimmune activity has become one the most successful strategies for autoimmunity therapy.
A new balance can be established with the removal of a key piece or blocking of a lethal move
so that the critical players are removed from the chessboard of an autoimmune response.
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As with any other disease involving the immune system, psoriatic manifestation begins with
Antigen-Presenting Cells (APC) activation by an unknown trigger. Different factors including
infections, trauma, medications, and emotional stress can initiate the initial phase of the
disease. Such factors can activate keratinocytes to release cytokines such as IL-1 and TNF-α,
initiating the effector phase of psoriasis by activating resident skin macrophages and Dendritic
Cells (DCs). DCs migrate to the regional lymph node, which initiates T lymphocyte activation
in response to the stimuli. This is part of the working model of the immune synapse of T cells
in psoriasis, integrating T cell signaling pathways in autoimmunity [29]. This association leads
to the production of IL-12/Th1/IFN-γ pathway. Many molecules in the plasma membrane of
both cells, other than the Major Histocompatibility Complex (MHC) and T Cell Receptor (TCR),
are involved in this phase and can be used as a target molecule for the treatment of psoriasis.
The most important molecules are ICAM-1, LFA-3, and CD80/CD86 in the DC and LFA-1, CD2,
and CD28 in the T cell, respectively. Alefacept, a fusion protein used for psoriasis treatment,
blocks T cells activation by interfering with CD2 on the T cell membrane, thereby blocking the
costimulatory molecule LFA-3/CD2 interaction [30]. Furthermore, it has recently been
discovered that IL-27 suppressed macrophage responses to TNF-α and IL-1β, thus identifying
an anti-inflammatory function of IL-27 [31].
Continuing the evolving complex immunological chess game, the activated T lymphocyte Th1
cytokine producers leave the lymph node and migrate to the skin where cytokines like TNF-
α, produced by keratinocytes and activated DCs, facilitate T lymphocyte diapedesis into the
dermis and epidermis [32]. The TNF-α induces the skin immune cell infiltration by inducing
chemokines and upregulating adhesion molecules on the endothelial cells of dermal vessels.
Adhesion molecules such as CLA and LFA-1 on the T lymphocyte membrane and E-selectin
and ICAM-1 on the endothelial cell membrane are involved in this process. Efalizumab, a
Humanized Anti-CD11a, Anti-LFA-1 molecule has been used in psoriasis treatment by
blocking the TL migration to the skin [33]. In summary, dendritic cells and effector T-cells are
important in the development of the psoriatic lesion, and cytokines produced by these cells
stimulate keratinocytes to proliferate and increase the migration of inflammatory cells into the
skin, promoting epidermal hyperplasia and inflammation [34].
3.1. Chessboard: The skin’s influence on psoriasis development
The primary cause of psoriasis has not been not found. Factors such as genetics and environ‐
mental exposure are now recognized to play a role in psoriasis development. Certainly,
autoimmunity does not appear to be the only, or necessary, component to the development of
psoriasis. However, psoriasis is a manifestation of skin immune reactions. Inflammation is a
key feature of pathogenesis, with all inflammatory cell types implicated in psoriasis pathology
by multiple interactions between cells of the skin or from other organs and the immune system.
Nonetheless, the etiology of psoriasis as an epidermal problem or a disease of faulty epider‐
mopoiesis due to impaired autocontrol mechanisms is not completely wrong. Keratinocyte-
derived inflammatory molecules ampliy skin immune responses associated with psoriasis, and
contribute to the disease process and clinical phenotype [35]. Psoriatic keratinocytes respond
aberrantly to cytokines and show altered intracellular signaling pathways [36].
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Heterogeneous functions of other skin resident cells, such as fibroblasts and endothelial cells,
may also contribute to the pathogenesis of psoriasis [37]. Furthermore, leukocytes that infiltrate
skin lesions have been shown to be involved in the pathogenesis of this disease [38]. Despite
parallels to the chicken and egg causality dilemma, all of these contribute to the presentation
in patients suffering from psoriasis that is later observed by clinicians.
3.2. Immunopathogenesis of psoriasis is a teleological model
From the previous data, it is well known that the immunopathogenesis of psoriasis is complex.
It involves alterations in the innate and acquired immunologic system. In the most accepted
models, cells of the skin when activated produce immunological mediators that act upon the
cells of the specific immune system. The action is amplified by the opposite direction [39].
The most studied theories about autoimmune disease etiology associate the immune dysre‐
gulation and loss of tolerance due to the impact of environmental factors on genetically
susceptible individuals. The literature has always highlighted the importance of the microor‐
ganism in the lack of immune homeostasis in psoriasis. The linkage of antigens of infectious
agents to the toll like receptors can activate keratinocytes and other cells to release innumerous
chemokines, cytokines and growth factors. Activated keratinocytes are capable of recruiting
and activating T cells. Therefore, infections are considered an important component that can
unleash the manifestation of psoriasis[40].
3.3. Dissociation between immunopathogenesis and immunological concepts
In accordance to the actual immunopathogenesis models for psoriasis, the skin is the body’s
primary defense against external invasion. However, the keratinocytes, in defending the body
against the microorganism, induces the migration of cutaneous lymphocyte-associated antigen
(CLA) positive T cells. Finally, T cells play a central role in initiating and perpetuating the
immunological mechanisms of psoriasis [41].
In this context, the possibility arises that endogenous, normal, housekeeping self-proteins
might be epitopic targets in autoimmune responses in psoriasis. The transition from self-
reactivity to the autoimmune pathology appears to be mediated by a complex network of
overlapping phenomena [42]. However, all studies about the antigen identification in psoria‐
sis, like in many other autoimmune diseases, did not find an optimal autoantigen for studying
the relationship between similarity level and immune responses [43].
Therefore, the actual models of immunopathogenesis of psoriasis break the specificity basic
statement of immunology. There are historical reasons for the dissociation between immuno‐
pathogenesis models and immunology concepts. Immunology emerged as a biomedical
science, concerned with host defense and production of anti-infectious vaccines. Ehrlich’s side-
chain theory explained the anti-infectious protection granted by vaccines and serotherapy [44].
It was the first steps of the development of initial cognitive metaphors, such as recognition and
memory.
The clonal selective theory of antibody formation in the 1950s was a new evolution and the
initiation of neo-Darwinism in Immunology. The selective theories of antibody formation
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resulted from the union of Immunology with Darwin’s theory of evolution. They also ampli‐
fied the “Defensive metaphors". Lymphocytes are supposed to respond specifically to stimuli.
Except for brief moments of activating or inhibiting interactions, lymphocytes are believed to
act independently from each other. Therefore, the immune system defends the body by
amplification of specific lymphocytes.
3.4. Defensive metaphor
In seeking to understand the unknown, mysterious, or abstract, the human mind draws
comparisons to the known, familiar, and concrete. When these comparisons are made explicit,
we call them metaphors or analogies. Scientists draw on metaphors when struggling with
phenomena that defy easy observation, such as the immune system. Immunology developed
many metaphors based on the scenario of its development. The naissance of immunology was
marked by the great World Wars and the Cold War tension. Consequently, immunological
concepts were simplified and described as war affairs.
The war metaphor for the immune response is appealing, in part, because it seems to create a
deeper understanding of the rules that direct the immune system actions. The consequence of
immunologists’ fondness for war metaphors, the authentication of the models has hardly been
tapped. However, any metaphors used to explain the immune system evoke intuitive notions
of strategy, skill and competition. Rarely do they indicate a deep understanding of the
particular clinical variation present in the arenas of medical life.
The underlying principle in this framework is the immune system as a "defense system.” When
it is said that the immune system defends the body, there is the use, intentionally or not, of a
metaphor. This is also a teleological argument (from the Greek τέλος for "end", "purpose", or
"goal"). Teleological argument is a knowledge or explanation about a fact that relates to a final
question. Teleological reasoning is an anthropomorphic interpretation used in science.
Therefore, it is given that there is an end or a function for the biological being or immune
system. However, there is not much teleological argument in physics or other natural science
fields. Do you know any reason why the earth gravitates around the sun?
Immunologists are in a comparable position to use metaphors inasmuch as the cellular and
molecular relationships that form the immune response are things that cannot readily be seen.
Famous and basilar modern immunological metaphors include viewing the immune system
as a planning body at a multidimensional space in which the lymphocytes are developing
defensive strategies against invaders or irritants. Another side of this favorite metaphor is that
of the main reason why bacteria invade the bodies is because those bodies harbor environments
where the bacteria can survive and multiply. The immune system protects the body from
invaders like bacteria, viruses and parasites.
There are consequences to this metaphor interpretation. The immune system does not act as
one structure or system. A system is described as a collection of elements connected to each
other in such a way that acting upon one element has repercussions upon all the others.
Lymphocytes are supposed to respond independently specifically to antigen stimuli. There‐
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fore, lymphocytes do not interact with the organism or with other lymphocytes. They are clonal
units. Thus, lymphocytes cannot organize themselves in a system.
In the actual stage of the clonal selection theory acceptance and consequent metaphor inter‐
pretation, the proposition of significantly different concepts or description of the immune
system have been excluded from the scientific media. The net result of such a theoretic
narrowness is the characterization of a massive variety of cellular or molecular independent
components involved in immunological activity. Therefore, the expansion, contraction and
regulation of specific clones of lymphocytes are insufficient to generate all known immuno‐
logical phenomena. Finally, the lack of a different view about the immune system followed in
a flagrant inability to create new vaccines, to understand and treat allergies or autoimmune
diseases as psoriasis.
3.5. Game theory as a new proposal for immunopathogenesis of psoriasis
Does the interpretation of the data in immunology, as it is today, represent the only possible
way to have an immune response? Is there a new model where the immune system can be
explained and the immunopathogenesis of autoimmune diseases as psoriasis can be inter‐
preted? This is a logical question that should follow the previous assumptions.
Consistent with the position that the details of a immune response matter, any other proposi‐
tion begins by reviewing and incorporating the accepted rules, constraints, and properties
available for the immune system - the Immunology game’s inner logic. The application of game
theory to Immunology thinking is our new proposition to explain autoimmune diseases and
other immunologic responses. The objective here is to begin taking games seriously as potential
sources of insight into the relationship that determines the Immune system.
Game theory is a set of concepts aimed at decision making in situations of competition and
conflict, as well as of cooperation and interdependence, under specified rules [45]. Game theory
metaphors began with the idea regarding the existence of mixed-strategy towards equilibrium.
The discordant note of this view of game theory with the actual immunological response is the
prevailing opinion among game theorists that any interaction will eventually converge to Nash
equilibrium predictions under the right conditions. Although the initial application of game
theory to immunology does not involve any of the requirements of the Nash equilibrium, the
human homeostasis conforms nicely to predictions of the Nash equilibrium or relevant
refinement. Absence of homeostasis or disease is the lack of stability in the immune system
concept.
Researchers are starting to realize that this simplistic view of the immune system as defensive
system needs a radical rethink [46]. The focus has been less on equilibria that correspond to a
notion of rationality or teleologism, but rather on ones that would be maintained by evolu‐
tionary forces. In this new view, the skin has no longer been thought of as a mere physical
barrier to attack by pathogens. Recent studies suggest the interplay between the skin's resident
microorganisms, known collectively as the skin microbiome, and immune mediated organ-
specific diseases [47]. Increasingly, it has been recognized that disruptions in the commensal
microflora may lead to immune dysfunction and autoimmunity. Therefore, the microbiome
Psoriasis - Types, Causes and Medication64
influence the host's immune system [48]. In particular, there are new findings on the role of
the microbiome in psoriasis [49].
Biologists have used game theory. The known game theory equilibrium in biology is the
evolutionarily  stable  strategy (ESS)  [50].  Additionally,  biologists  have used evolutionary
game theory and the ESS to explain many seemingly incongruous phenomena in nature.
Paradoxically, it has turned out that game theory is more applied to biology than to the
field of immunology for which it can be an evolutionary metaphor. Considering some of
the ways in which game metaphors  have been used in biology analysis,  observing that
most game metaphors involve only vague and fleeting references to some generic game
with the goal of making a preconceived point. We contrast this with analogies in the natural
sciences, in which knowledge of a well-understood phenomenon is used to shed light on
another that  is  less well  understood. A new idea has to propose a nonteleological  view
including  all  possible  natural  evolutions,  which  will  necessarily  generate  other  set  of
problems and enigmas. A nonteleological thinking is a way of viewing things as they are,
rather than seeking explanations for them [51]. However, the practicality of a nonteleolog‐
ical view in immunology is null nowadays [45].
In summary, although the costs of infections to immune system are meaningful, a growing
body of evidence supports a general benefit associated with infectivity. Reducing the risk of
uncontrolled inflammation and limiting the tissue damage caused by injury are important
features of host defense against pathogens, but would be beneficial in a variety of autoimmune
diseases [52]. Game theory may help to appreciate the benefits of immunity to infection. This
is the challenge for the new homeostatic immune system metaphors that explain the autoim‐
munity mechanisms as in psoriasis.
4. The initial biologic treatments for psoriasis and implications for the
understanding of immunological mechanism of psoriasis
Psoriasis was defined as Th1 type of disease based on the early understanding of the T helper
subsets. The initial belief was that infiltrating T cell subpopulations derived from the draining
lymph node regulated the development of the inflammatory responses in the skin by produc‐
ing IFN-γ and TNF-α [53]. The Th1-derived cytokines produced by these infiltrating Th1 favors
further Th1 cell access, upregulates keratinocyte chemokine production, and supports dermal
DC myeloid type (DC11c+) activation. In response to this cytokine activation, keratinocytes
and other cells produce a plethora of immune mediators, which induce and amplify inflam‐
matory responses in the skin [54].
As a result, two logical biologic therapeutic approaches were tested: one was the administra‐
tion of counter regulatory type 2 cytokines and the second was the blocking of type 1 cytokines.
The use of monoclonal antibodies or fusion proteins to neutralize cytokines started to be used
on a large scale because of their efficacy and practicality.
These studies have proved to be a useful biological model and test ground for evaluation of
the skin immune system and psoriasis. Although these drugs were not initially developed in
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the treatment of psoriasis, but rather in rheumatoid arthritis and Crohn’s disease, the obser‐
vation that Crohn’s disease patients with psoriasis were improving while on anti-TNF therapy
profoundly influenced the studies that were to come [55].
Although clinical response to anti-TNF suggested a role for Th1 cells in psoriasis, evidence
coming from other studies demonstrated that Th1/Th2 paradigm and key role of TNF were
not sufficient to explain the full pathogenesis of psoriasis. At this point some academic
resistance to an immunological pathogenesis for psoriasis was raised [56]. However, the main
interpretation was that an important piece of the immunological cytokine puzzle was missing.
Many other pieces would be involved in such a complex game.
5. The IL–12/23 and its role in the immunopathogenesis psoriasis
The initial quest for the missing cytokines was the search for pathway inducers. Researchers
first noted that IL-12 is crucial for Th1-cell differentiation [57]. IL-12 signaling via its receptor
activates Stat4 (signal transducer and activator of transcription 4), which upregulates IFN-γ.
IFN-γ activates Stat1, which enhance T-bet (T-box expressed in T cells), the leading TH1
transcription factor, further enhancing IFN- γ production and downregulating IL-4 and IL-5
expression [58]. IFN-γ mediates many of the pro-inflammatory activities of IL-12. Phagocytes
and Dendritic Cells (DCs) are the main producers of IL-12 in response to microbial stimulation
[59], and this relationship links innate resistance and adaptive immunity. The main function
of IL-12 is resistance to infections with bacteria and intracellular parasites. However, it plays
an important role in the Th1 response that sustains organ-specific autoimmunity [60]. The use
of anti-IL-12 mAb (monoclonal antibody) in an experimental model of psoriasis also suggested
the therapeutic value of blocking IL-12 in humans [61], although side effects of the drug limited
further development in this area.
For many years, the IL-12-dependent Th1 cells were thought to be essential for the induction
of autoimmunity. However, during the Th1/Th2 paradigm studies, an IFN-γ-independent
mechanism responsible for the pathogenesis of many inflammatory diseases and psoriasis was
found [62]. IL-12 and IL-23, as discovered previously from human DNA sequence information,
share the subunit p40 [63]. The use of anti-IL-12/23p40 and anti-IFN mAb ultimately estab‐
lished at least part of the solution to the riddle. Only neutralization of p40, but not of IFN-γ,
ameliorated chronic inflammatory reactions. This finding suggested that the latter cytokine,
IL-23, accounted for the IFN-γ-independent mechanism of inflammation.
Identified from human DNA sequence information, IL-23, like IL-12, is also a heterodimeric
cytokine composed of the same subunit p40 paired with the unique p19 [64]. It has been
reported that IL-12 and IL-23 are up-regulated in psoriatic skin [65]. Human studies with anti-
IL-12p40 have shown that this treatment not only ameliorates psoriasis, but also down-
regulates type 1 cytokines and IL-12/IL-23 in lesional skin [66]. Besides sharing the subunit p40
and signaling through similar receptors, IL-23 and IL-12 are responsible for driving different
T-cell subsets. Moreover, presence of abundant IL-23+ dendritic cells as well as elevated mRNA
expression for both subunits of IL-23 (IL-23p19 and IL-23p40) in psoriatic lesions supports the
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role of IL-23 in the pathogenesis of psoriasis [65, 67-69]. Genetic studies have revealed that
polymorphisms in IL-23p19, IL-12/23p40, and IL-23R are associated with increased risk of
psoriasis [70-72]. Furthermore, in an animal xenograft model of psoriasis, Tonel G et al showed
that treatment with anti human IL-23 mAb causes statistically significant reduction of
acanthosis and papillomatosis index in grafts of mice in comparison to isotype controlled mice.
Moreover, they found comparable efficacy of anti human IL-23 mAb with anti TNF-α
(infliximab) in blocking the development of psoriasis. They also showed a significant decrease
in CD3+ T cells mainly in the epidermis of mice treated with anti human IL-23 mAb in
comparison to control mice [73].
IL-23 could also mediate and sustain late-stage chronic inflammation by the production of
IL-17 by Th17 [74]. IL-23 plays an important role as a central growth factor [75-77]. In presence
of TGF-β and IL-6, IL-23 helps in development of Th17 cells whereas TGF-β is inhibitory to
production of IL-22 [78-80] (Figure 2).
Figure 2. The pivotal role of some of IL-12 and IL-23 in psoriasis etiopathogenesis: How blocking the effects of these
cytokines substantially improve the disease condition.
The IL-23/Th17/IL-17 immune axis was initially elucidated when IL-17 gene expression was
induced by B. burgdorferi independent of IL-12 [81]. The IL-17–producing CD4+ T cells distinct
from those producing either IL-4 or IFN-γ were called Th17 [82]. Patients with psoriasis have
increased Th17 cells as well as increased expression of mRNA for Th17 cytokines (IL-17A;
IL-17F; TNF-α; IL-21 and IL-22) and chemokines (CCL20) [83-87]. In psoriasis, Th17 cytokine
IL-17A mainly induces cytokine and chemokine production by keratinocytes [84, 88, 89],
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whereas IL-22 induces proliferation of keratinocytes and production of antimicrobial peptides
by keratinocytes [78, 90-92]. The role of IL-23 and IL-17 in psoriasis was further substantiated
in some animal studies with recombinant IL-23 and anti IL-17A. In wild type (WT) mice,
injection of recombinant murine (rm) IL-23 induces epidermal hyperplasia [93, 94], whereas,
in IL-17 -/- mice showed less epidermal hyperplasia after repeated injection of rmIL-23. A
recent publication by Rizzo et al showed that WT mice do not show epidermal hyperplasia to
injection of rmIL-23 if they were treated with anti IL-17A antibodies [95]. A redundant cytokine
model has emerged as the evolving explanation for psoriasis pathogenesis. It is based on the
IL-12/Th1/ IFN-γ - TNF-α and the IL-23/Th17/IL-17 immune pathways (Figure 3). The
effectiveness of the anti-TNF treatment of psoriasis validated the first axis. The efficacy of anti-
p40 (anti-IL12/23) treatment confirms the other [96].
Figure 3. Time line of development of psoriasis pathophysiology: From complex immunological disease through ge‐
netic participation until recent advances.
6. Selective IL–23/Th17/IL–17 immune axis inhibition
IL-23 favors the proliferation of the Th17 subtype and consequent production of IL-22 and IL-6
that stimulates the proliferation of keratinocytes. IL-17 favors infiltration of neutrophils into
the skin forming the typical Munro’s micro-abscesses with some participation of IL-22 [97].
Studies have demonstrated that anti-p40 (anti-IL-12/23) treatment is highly efficacious for
psoriasis. Ustekinumab anti IL-12/23 antibody showed its efficacy and safety in three phase III
trials recruiting 2899 patients. From two placebo controlled trials, PHOENIX 1 and PHOENIX
2, ustekinumab showed its efficacy in ameliorating psoriatic plaques, pruritus, and nail
psoriasis [98]. (Table 1).
Remarkably, in a phase II multicenter, randomized, double-blind, placebo-controlled trial
briakinumab, another human monoclonal anti-IL-12/23 antibody, 90-93% of subjects in 4
dosing groups were able to achieve a PASI 75 [99]. This finding alone confirms the centrality
of this pathway because these levels of efficacy have not been previously seen in studies with
other agents [100]. Safety data for both agents is limited, but to date has been favorable.
One issue with anti-p40 therapy is that it inhibits both the classical IL-12/Th1/IFN-γ and IL-23/
Th17/IL-17 immune pathways. IL-12 and IL-23 are related cytokines with differences in their
biological activities. After binding to their receptors, different intracellular transcription
complexes are activated [101]. IL-12 predominantly acts on naïve T cells and initiates the TH1
Psoriasis - Types, Causes and Medication68
response. In contrast, IL-23 primarily affects memory T cells and expands the initiated Th1
inflammatory response by Th17 activity and maintains an adequate memory pool by com‐
promising memory T cells [64, 101, 102]. Experimental studies suggest that IL-23/Th17/IL-17
immune axis blocking is sufficient to treat autoimmune inflammation [63].
Another way to block both pathways is the immunoregulatory role of IFN-γ. It is well-known
that the administration of anti-IFN-γ induces exacerbation of Experimental Autoimmune
Encephalomyelitis (EAE) [103]. One possible explanation is the inhibition of IL-12/Th1/IFN-
γ axis may destroy the regulatory role of IFN-γ during chronic inflammation. TNF-α, like INF-
γ, has a regulatory role in the immune system [104]. This might explain the observation that
anti-TNF therapies can induce psoriasis and other autoimmune diseases in some patients [105].
An increase in efficacy and reduction of adverse events are the main drivers for new therapies.
Infections, one type of adverse event, usually increase in patients receiving anti-cytokine
therapy [106]. Studies with anti-IL-23 therapy will require surveillance for the development
of opportunistic infections. Reports from patients with IL-12 and/or IL-23 cytokine deficiency
syndromes alert to these potential infections in individuals under anti-IL-23 therapy. Invasive
salmonellosis and mycobacterial diseases were present more often in patients with IL-12/IL-23
deficiency indicating that immunity against these microorganisms appears to be dependent
of IL-12 and/or IL-23 [107]. However, antibodies against IL-12 and IL-23 may not cause a
complete inactivity of these cytokines in a clinical scenario. For example, an experimental study
showed that IL-23 plays a role in host defense against P. carinii, but it is not an essential one
[108]. Clinical studies with anti-IL-12/23 treatment thus far have not increased the risk of non
* P <0.001 Adapted from: Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human
interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind,
placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371(9625):1675-1684.
Table 1. Clinical improvement at week 12 (PHOENIX II)
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opportunistic or opportunistic infections [109]. A recent study showed that blocking IL-23 with
monoclonal antibodies during BCG infection does not appear to affect the bacterial burden in
immunocompetent mice. In contrast, blocking TNF-α or both IL-23 and IL-12 with anti-p40
dramatically enhances mycobacterial growth. From this study, antibody blockade of IL-23
alone rather than IL-12 might be preferable in patients who have been, or may be, exposed to
mycobacterial infection [110].
7. A new piece and a new move
As previously mentioned, the IL-23 favors the proliferation of the Th17 and consequent
production of IL-22. IL-22 mRNA presence was initially described in IL-9 stimulated T-cell
lines and in concanavalin A (Con-A)-activated murine spleen cells [111]. Further studies
demonstrated that IL-22 expression can only be observed in activated immunological cells
[112]. However, other reports have revealed that some T cells express IL-22 independently of
IL-17 [113]. Finally, a new distinct human memory CD4+ T cell subset with skin-homing
properties was identified and denominated Th22 [114].
A preferential  production of  IL-22 cytokine by T cells  (Th22,  Th17,  and Th1)  is  present
in psoriasis  lesions [86].  Many animal models indicate the role of  IL-22 in psoriasis.  IL-22
over-expressed  transgenic  mice  developed  psoriasis-like  skin  lesions  [115].  In  IL-22  -/-
mice,  injection of  IL-23 fails  to  induce epidermal hyperplasia  indicating the role  of  IL-22
as  a  downstream  mediator  of  tissue  effects  caused  by  IL-23  [78].  In  a  recent  publica‐
tion,  Rizzo  HL  et  al  showed  that  to  have  IL-23  mediated  epidermal  hyperplasia,  both
IL-17  and  IL-22  is  required;  any  one  of  these  is  not  sufficient  to  execute  the  effect  of
IL-23.  They also showed that  pre-treatment with anti  IL-22 or  anti  IL-17A Abs block the
rmIL-23  mediated  epidermal  hyperplasia  in  wild  type  mice  [95].  In  reconstituted
epidermis  model,  IL-22  produces  acanthosis  dose  dependently,  which resembles  psoria‐
sis  and  either  one  of  these  alone  is  not  sufficient  to  execute  the  effect  of  IL-23.  The
effects  of  IL-20  subfamily  cytokines  on  reconstituted  human  epidermis  suggest  poten‐
tial  roles  in  cutaneous  innate  defense  and  pathogenic  adaptive  immunity  in  psoriasis
[92].  In  a  study  by  Wolk  K  et  al,  a  correlation  was  demonstrated  between  the  plasma
IL-22 levels  and the severity of  the disease [90].  IL-22 regulates  the expression of  genes
responsible  for  antimicrobial  defense,  cellular  differentiation,  and  mobility  in  keratino‐
cytes  and may play a:  a  potential  role  in  psoriasis  [90].  Moreover,  IL-22 levels  correlat‐
ed  with  IL-20  levels,  which  is  in  accordance  with  the  IL-22-induced  keratinocyte  IL-20
production  [116].  This  suggests  that  IL-22  and  its  downstream  mediator  IL-20  play  an
important  role  in the final  steps of  psoriasis  pathogenesis.  Sabat  R and his  group in their
studies showed that  IL-22 regulates  keratinocyte function in several  ways:  a.  IL-22 helps
form a biological  barrier  of  the skin by producing antimicrobial  proteins (AMPs) like β-
defensins,  and S100 proteins.  This  may be one of  the reasons that  psoriatic  patients  have
less  skin  infections.  b.  IL-22  interferes  with  physiological  desquamation  process  of  skin
by  inhibiting  the  terminal  differentiation  of  keratinocytes.  c.  IL-22  plays  a  role  in
recruiting neutrophilic  granulocytes  in  skin by inducing the  production of  chemokines;.
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d.  IL-22  indirectly  helps  in  extracellular  tissue  degradation  by  inducing  production  of
matrix  metalloproteinases  1  and 3.  IL-22 induces  the production of  IL-20,  another  IL-10
family cytokine which has similar  effects  as  IL-22,  thus resulting in amplification of  the
effects  of  IL-22 [117].  In a  transgenic  mouse model,  it  has been showed that  IL-22 causes
acanthosis,  hyperkeratosis,  and  hypogranulosis,  which  are  hallmarks  of  psoriasis.  IL-22
acts  through  STAT-3  to  impact  the  differentiation  of  keratinocytes  [115].  IL-22  induces
pro-inflammatory chemokines and antimicrobial  proteins (AMPs) β-defensins (BDs),  and
promotes  epidermal  acanthosis  and  parakeratosis  of  keratinocytes  [90,  118,  119].  Some
synergistic  effect  was  noted  with  other  pro-inflammatory  cytokines  like  TNF-α;  IFN-γ;
and IL-17 [117].  Alone,  TNF- α does not  have much effect  on terminal  differentiation of
keratinocytes,  but  when  keratinocytes  were  co-cultured  with  IL-22  and  TNF-  α,  the
effects  of  IL-22 were amplified.  This  kind of  synergism was also seen with CXCL8 and
IL-20  expression  in  keratinocytes  co-stimulated  with  IL-22  &  TNF-α.  One  possible
explanation of  this  may be that  TNF-α increases the expression of  IL-22 receptor complex
and also  affects  the  IL-22  signaling pathway [115].  Thus,  IL-22  and IL-20,  but  not  IFN-
γ or IL-17,  are the key mediators  of  resulting epidermal proliferation.  IL-22 acts  through
heterodimeric  receptor  complex  composed  of  IL-22R1  and  IL-10R2  [120].  IL-10R2  chain
is  ubiquitously  expressed  in  all  cells  and  is  important  component  of  receptor  com‐
plexes  required  for  IL-22,  IL-10,  IL-26  and  IL-28  and  IL-29,  whereas  the  IL-22R1  chain
is  present  in epithelial  cells  and hepatocytes [121].  Between the two subunits,  IL-22 binds
first  to  IL-22R1,  the  high-affinity  receptor,  and  then  IL-10R2,  a  lower  affinity  receptor
[122].  To  produce  its  effect,  IL-22  acts  through  different  signaling  pathways,  mainly
signal  transducer and activator of  transcription 3 (STAT-3)  and mitogen activated protein
kinase [123].
This final move induces the vicious cycle of proliferation and inflammation of the skin
characterized by the hyper-proliferative phenotype of keratinocytes in psoriasis. An anti-IL-22/
IL-20 approach would have a complementary role to the neutralization of p40. However, there
has not yet been a human study to demonstrate such a role or anti-IL-22 therapy in the
treatment of psoriasis.
8. The other side of the chessboard: The role of T reg
Today, reading a book or scientific article on immunopathogensis, one will observe that
suppressor T cells, renamed regulatory T cells (Tregs), have become a central concept in
immunological vocabulary [124]. Hundreds of publications on Tregs have validated the
existence of this single line of T cells. The CD4+CD25+highFoxp3+ Treg subpopulation is
developed in the thymus and may be peripherally induced during the course of a normal
immune response. The model in which Tregs directly or indirectly modify activation and
differentiation of pathogenic T cells by means of an effect on antigen-presenting cells is
supported by in vivo analyses [125].
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8.1. Regulatory T cells: Development of an immunological concept
Biological systems are subject to complex regulatory controls and the immune system is no
exception. It is known that the immune system has the potential to generate lymphocytes
against auto-antigens. Experiments, however, suggest that individuals cannot easily be
immunized against their own tissues. Therefore, a suppression mechanism is necessary to
control potentially pathogenic immune cells. Owen suggested that this tolerance against one's
own tissues is acquired during the development of the immune system, and Burnet proposed
that the clonal selective destruction of lymphocytes for auto-antigens occurs primarily in the
thymus.
The destruction of auto-reactive lymphocytes is the primary mechanism that leads to tolerance,
but we know that this system is not perfect. Self-reactive B and T lymphocytes can be isolated
from normal individuals [126]. Nishizuka and Sakakura proposed another mechanism for
controlling auto-reactive cells. They observed that mice thymectomized between the second
and fourth days of life developed an organ-specific autoimmune disease. This target-organ
destruction can be prevented by restoring T cells from genetically identical individuals. The
generation of regulator T cells was proposed in order to explain this mechanism of auto-
tolerance attributed to the thymus [127].
Other studies observed that the prevention of autoimmune diseases was diminished by the
reduction of CD4+ T cells, but not of CD8+ T cells, indicating that regulatory cells belonged to
the CD4+ T cell class of lymphocytes. Sakaguchi subsequently characterized these regulatory
cells as natural CD4+CD25+ Tregs that express Foxp3 [128].
8.2. Suppressor T cells: Regulatory T cells are suppressor T cells
Another control point of the immune response is established when the normal immune
response is initiated. A different mechanism must be set off in order to control the magnitude
of the response and its subsequent termination. This regulation should contribute to limiting
clonal expansion and effector cell activity. Soon after the discovery that T lymphocytes function
as helper cells for B-lymphocytes, RK Gershon proposed that they could also act as cells capable
of suppressing the immune response [129]. This subpopulation of suppressor T cells was
considered a controller of both auto-reactive and effector cells. A suppressor cell was func‐
tionally defined as a lymphocyte that inhibits the immune response by influencing the activity
of another type of cell involved in a cascade of suppression factors, a network of anti-idiotypic
T cells, and counter-suppressive cells [130].
Many of the experiments carried out contain data that support the existence of suppressor T
cells. However, the mechanism responsible for these suppressive phenomena was never
clearly characterized, and consequently interest in the field of suppressor T cells has gradually
dwindled. The discovery of Th1/Th2 cells led researchers to abandon the concept of suppressor
T cells. Suppression was instead attributed to counter-regulatory cytokines. As pointed out by
Green and Webb, the letter ‘‘S'' started to resemble a foul word in cellular immunology, and
its use was considered synonymous of scarce data with excessive interpretation or a mystic
phenomenon [131].
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Suppressor T cells reappeared as regulatory T cells (Tregs) in the late 1990s when several
subpopulations of T cells were identified as having the capacity to inhibit the proliferation of
other cells. Shevach et al. were the first to call attention to the fact that regulatory T cells and
suppressor T cells are the same [132]. Therefore, the term ‘regulatory' gradually replaced the
term ‘suppressor'. The main problem, however, is not that cells are termed regulatory, but that
they are considered to be suppressors. It is more appropriate to consider regulatory T cells as
immune response directors instead of its suppressors.
9. Regulatory T cells and psoriasis
The regulation mechanism of the immune system by CD25+high Tregs is not well understood.
Studies have not yet arrived at a simple mode of action. Whatever the mechanism, the
homeostatic balance of the immune system is obtained by healthy cellular and humoral
responses. Some inflammatory agents, whether physical, chemical, or infectious, induce an
intense immune response. This immune response against them frequently results in tissue
damage that could be more intense if it were not for the interference of regulatory mechanisms
[133]. As has already been specified, Treg cells help limit the damage caused by a vigorous
immune response. Natural Treg cells may respond to an ample variety of auto-antigens,
although there is evidence that they may also respond to antigens expressed by microbes.
Induced regulatory T cells, such as TR1 or Th3, may develop from CD4+ T cells when exposed
to specific conditions [134].
Similarly, excessive activity of Treg cells may limit the magnitude of the immune response,
which may result in failure to control an infection. On the other hand, the absence of the T
regulator may result in intense inflammation and autoimmune dermatitis. Tissue damage may
also result from the development of effector cells against their own auto-antigens (Figure 4).
Psoriasis is sustained by the activation of pathogenic T cells. The regulatory expression of skin
diseases discusses the action exerted by regulatory T cells, especially CD4+CD25+high Tregs
on psoriasis. Various types of influence of these cells suggest that they may act by suppressing
or augmenting immunity [135, 136]. The control of Treg cells may affect the results favorably
or may be deleterious. There is no definitive view. In psoriasis, studies have shown that the
subpopulation of CD4+ T lymphocytes in peripheral blood, phenotypically CD25+high,
CTLA-4(+), Foxp3high, is deficient in its suppressor functions. This is associated with an
accelerated proliferation of the CD4+ T cell response [137]. The presence of non-functional
CD4+CD25+high Treg cells in peripheral blood and in tissues may lead to a reduced capacity
to contain pathogenic T cells and to a hyperproliferation of the psoriatic plaque in vivo. These
findings represent a critical component of this autoimmune disease and may have implications
for potential therapy by manipulation of CD4+CD25+high Tregs in vivo. However, other
factors, such as the immune status and genotype, and the presence of concomitant diseases or
other infections may also have an influence. The manipulation of this balance can be explored
therapeutically.
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Figure 4. Immune response regulation mechanisms. The force balance between Tregs and the effector T CD4+ cells
may present in a different manner depending on being an autoantigen or a pathogen. In A portion, the clinical ex‐
pression of autoimmune skin diseases is shown. In this case, there is clinical manifestation only when the number and
function of Tregs are significantly reduced. B portion displays clinical manifestations that may occur in extreme cases.
In case of excessive Treg function, the result shows reduction of effector lymphocytes against the pathogen, an in‐
crease in its number and less tissue damage. The contrary applies to effector cells against the pathogen that surpass
the number and function of Treg. The ideal immune and clinical response occurs when there is a balance between
functions
9.1. Clinical and therapeutic consequences of regulatory T cells
An improved understanding of the role of T regulators in psoriasis may lead to the identifi‐
cation of new targets for treatment. More specifically, the goal is to manipulate natural
regulator cells or those induced by means of an increase or decrease of their function, depend‐
ing on the circumstances.
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Auto-injections of regulatory T cells are a promising approach to modulation of inflammation
and autoimmune diseases [138]. Nevertheless, there is a significant decline in the function of
natural CD4+CD25+high Treg cells of peripheral blood in patients with autoimmune diseases
when compared to that of healthy individuals. In order to overcome this difficulty, cytokines
were used to stimulate the growth of regulator T cells. IL-15 allows a significant in vitro
expansion of regulator cells [139]. Natural CD4+CD25+high Treg cells obtained by ex vivo
expansion through stimulation with allogeneic antigen-presenting cells and IL-2 were capable
of modulating the graft-versus-host disease (GVHD). Induction of natural CD4+CD25+high
Treg cells may facilitate the establishment and maintenance of immunological tolerance.
Depletion of natural CD4+CD25+high Treg cells may be an effective way of reversing the
tolerance induced by malignant tumors and increasing the activity of the immune system
against cancer epitopes [140].
In the field of dermatology, the stimulation of Treg cells may be important in autoimmune
diseases. For example, blockage of T lymphocyte stimulation, as in the use of the antibody
associated with CTLA-4 (cytotoxic T lymphocyte-associated antigen 4-immunoglobulin,
CTLA4Ig), reverts the development of psoriatic plaques [141]. In the clinical context, the effect
of immunomodulator drugs on these cells warrants attention. For example, tacrolimus, an
inhibitor of calcineurin, increases the inhibition of Treg cells in atopic dermatitis [142, 143].
Fludarabine reduces the frequency and suppressive function of natural CD4+CD25+high Treg
cells [144]. Low doses of cyclophosphamide induce the inhibition of natural CD4+CD25+high
Treg cells and consequently increase the immune response in an apparently paradoxical effect
[145]. Along the same line, cyclophosphamide decreases the function, proportion, and number
of natural CD4+CD25+high Treg cells that suppress the induction of contact hypersensitivity
[146, 147]. Currently, topical corticosteroids constitute one of the most effective treatments for
psoriasis and other inflammatory skin diseases. These drugs are effective in inhibiting the
function of Th2 cells, eosinophils, and epithelial cells. However, treatment with these drugs
during the presentation of the epitope may result in an increased tolerance by suppressing the
development of dendrite cells that secrete IL-10, which are necessary for the induction of T
regulators. Therefore, treatment with corticosteroids may increase the subsequent effect of the
T response and aggravate, on the long run, the course of inflammatory diseases [148]. This
aspect may also be related to the rebound effect of inflammatory diseases once these drugs are
removed.
10. What is new?
Studies suggest that IL-23/Th17/IL-17 immune axis blocking can be used to treat psoriasis [63].
Ustekinumab, anti IL-12/23 antibody, showed its efficacy in ameliorating psoriatic plaques,
pruritus, and nail psoriasis [98]. This stimulated growing interest in the therapeutic potential
of agents such as brodalumab, ixekizumab, and secukinumab that inhibit interleukin-17
signaling. These new group of biologics are in clinical trials. They use cytokine neutralization
and receptor antagonism in treating psoriasis. Secukinumab and ixekizumab specifically
Psoriasis as a Chess Board — An Update of Psoriasis Pathophysiology
http://dx.doi.org/10.5772/53580
75
neutralize interleukin-17A, whereas brodalumab is an antagonist of the interleukin-17RA
receptor [149-151].
As previously mentioned, IL-23 favors the proliferation of the Th17 and consequent production
of IL-22. Fezakinumab (ILV-094, Pfizer) is a fully human monoclonal IgGγ antibody to IL-22
under study for the treatment of rheumatoid arthritis and psoriasis [152].
Nonetheless, there is no single new data about the basic mechanisms of psoriasis development
despite the cytokine and anti-cytokine therapies widely used.
11. Conclusion
In medicine, a gold standard is the intervention believed to be the best available option. Given
the proven role of many cytokines in psoriasis, substantial interest exists in targeting them
with neutralization immunotherapy. If Th1/Th17/Th22 pathways operate in different steps of
psoriasis development, then targeted blockade place biologics as the standard-setting para‐
digm for therapy and understanding of the pathogenesis of psoriasis. However, large studies
are needed to provide information on the therapeutic effects, adverse events of any anti-
cytokine therapy, and their place in the treatment of psoriasis and other skin diseases. To
complement this approach, a detailed comprehension of the associations among the various
regulator cells may help in understanding the events leading to the genesis of skin diseases.
Ultimately, an ability to manipulate the function of regulator T cells according to the desired
therapeutic effect will be the goal. Together, an integrated immunologic approach to therapy
holds great promise in reducing the burden of psoriatic disease.
Now that cytokine and anti-cytokine therapies are increasingly used, it is a great opportunity
to learn in detail the complex action of these molecules, including both their pro-inflammatory
and immunosuppressive properties. The data present above clearly indicate that autoimmun‐
ity is a complex system. The immune response seems to be in a constant balancing act with
itself. Emerging data indicate that a more realistic view is that these cytokines are not especially
loyal to their functions. They switch sides, meaning that they do not have simple pro- or anti-
inflammatory actions.
Therefore, the mechanisms of action of the biologic therapies are more intricate than a simple
blocking effect. The same cytokine can promote immune and inflammatory responses in some
circumstances and inhibit responses in other settings. There is good and bad in every cytokine.
Finally, the gut, skin or oral microbial communities simply primes the immune system.
Therefore, psoriasis is a game played by many pieces and movements on a complex chess‐
board. The combinations of movements (cytokines) exert variable effects at different times
during the evolution of autoimmune disease. There is much left to be done to dissect the
complex and highly interactive effects of the players that one would have thought we under‐
stood very well, the Immunology game’s inner logic. The application of game theory to
Immunology thinking is our new proposition to explain autoimmune diseases and other
immunologic responses. The objective is taking game theory seriously as a potential source of
insight into the complex relationships that determine immune system function.
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